盐酸缬更昔洛韦片怎么用呢？

As a systemic antiviral drug, valganciclovir hydrochloride tablets are suitable for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis, and for the prevention of CMV infection in high-risk solid organ transplant patients. Valganciclovir hydrochloride tablets are sensitive to human viruses including human cytomegalovirus (HCMV), and valganciclovir hydrochloride tablets are sensitive to herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV) and hepatitis B virus.

Instructions for taking Valganciclovir Hydrochloride Tablets:

Adult patients should use Vancevir tablets rather than Vancevir oral solution. Oral solutions and tablets should be taken with food. Vancevir tablets should not be broken or crushed. Before dispensing medication to patients, pharmacists must prepare oral solution (50 mg/ml) with Vancevi. 

Recommended dose in adults with normal renal function: Treatment of induction of cytomegalovirus retinitis: The recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. 

Maintenance: After induction therapy, or in adult patients with inactive cytomegalovirus retinitis, the recommended dose is 900 mg orally once daily. 

Cytomegalovirus prophylaxis: For adult patients who have received a heart or kidney-pancreas transplant, the recommended dose is 900 mg orally once daily starting within 10 days of transplantation and continuing until 100 days after transplantation. 

For adult patients who have received a kidney transplant, the recommended dose is 900 mg taken orally once daily starting within 10 days after transplantation and until 200 days after transplantation. 

Recommended dosage for pediatric patients

Prophylaxis of Cytomegalovirus (CMV) in Pediatric Renal Transplant Patients: For pediatric renal transplant patients 4 months to 16 years of age, the recommended once-daily mg dose (7 × BSA (bovine serum albumin) × CrCl (creatinine clearance)) should be initiated within 10 days after transplantation and continued until 200 days after transplantation. 

Prophylaxis of Cytomegalovirus (CMV) in Pediatric Heart Transplant Patients: For pediatric heart transplant patients 1 month to 16 years of age, a once-daily mg dose (7 × BSA (bovine serum albumin) × CrCl (creatinine clearance)) is recommended starting within 10 days after transplantation and continuing until day 100 after transplantation.